Loading...
•
Dec 31, 2021
CRISPR Therapeutics Q4 2021 Earnings Report
CRISPR Therapeutics reported financial results for Q4 2021, highlighting progress in clinical programs and collaborations.
Key Takeaways
CRISPR Therapeutics reported a net loss of $141.2 million for the fourth quarter of 2021, compared to a net loss of $107.0 million for the fourth quarter of 2020. The company's cash, cash equivalents, and marketable securities totaled $2,379.1 million as of December 31, 2021. Total collaboration revenue was $12.3 million for the fourth quarter of 2021 compared to $0.2 million for the fourth quarter of 2020.
More than 70 patients have been dosed with CTX001 across CLIMB-Thal-111 and CLIMB-SCD-121, with enrollment complete and regulatory submissions planned for late 2022.
Initiated and began dosing patients in the pivotal trial of CTX110, targeting CD19+ B-cell malignancies, with additional data expected in 2022.
Top-line data expected in 1H2022 for ongoing CTX120 and CTX130 clinical trials.
First patient dosed in Phase 1 clinical trial of VCTX210 for the treatment of type 1 diabetes (T1D).
CRISPR Therapeutics
CRISPR Therapeutics
CRISPR Therapeutics Revenue by Segment
Revenue by Segment
Collaboration Revenue
CapyFin.comGrant Revenue
CapyFin.com Forward Guidance
CRISPR Therapeutics anticipates continued progress across its portfolio in 2022, expecting a productive year as it enters a new phase of growth.
Positive Outlook
- Planned regulatory submissions for CTX001 in late 2022.
- Additional data expected to be reported in 2022 for CTX110 pivotal trial.
- Top-line data expected in the first half of 2022 for CTX120 and CTX130 clinical trials.
- Advancement of in vivo programs with multiple programs expected to move into the clinic in the next 18 to 24 months.
- Strong capital position to advance pipeline and platform.
Challenges Ahead
- Uncertainties inherent in the initiation and completion of preclinical studies.
- Uncertainties about regulatory approvals to conduct trials or to market products.
- Potential impacts due to the coronavirus pandemic.
- Uncertainties regarding the intellectual property protection.
- Future competitive or other market factors may adversely affect the commercial potential for CRISPR Therapeutics’ product candidates.
Revenue & Expenses
Visualization of income flow from segment revenue to net income